Clinical guidelines support the use of fluciclovine F 18 injection as an imaging option for prostate cancer recurrence or progression1,2

National Comprehensive Cancer Network® (NCCN®)1

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer Version 2.20181 state that F-18 fluciclovine PET/CT or PET/MRI should be considered as options in the clinical workup of patients with recurrence or progression of their prostate cancer.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

NCCN Categories of Evidence
NCCN Categories of Evidence

To view the full NCCN Clinical Practice Guidelines in Oncology in Prostate Cancer Version 2.2018, click here.

American College of Radiology (ACR)2

The ACR Appropriateness Criteria® for Post-Treatment Follow-up of Prostate Cancer categorizes Axumin PET/CT skull base to midthigh as “usually appropriate” for post treatment follow up in the following situations:

  • Variant 1: Prostate cancer follow-up. Status post radical prostatectomy. Clinical concern for residual or recurrent disease.
  • Variant 2: Prostate cancer follow-up. Clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments.
  • Variant 3: Metastatic prostate cancer treated by systemic therapy (androgen deprivation therapy [ADT], chemotherapy, immunotherapy). Follow-up.

To view the full ACR Appropriateness Criteria® for Post-Treatment Follow-up of Prostate Cancer, click here.

References

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Guideline for Prostate Cancer (Version 2.2018). © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed 03/08/2018. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. Froemming AT, Verma S, Eberhardt SC, et al., for the Expert Panel on Urologic Imaging. American College of Radiology, ACR Appropriateness Criteria® (Post-treatment Follow-up of Prostate Cancer). © 2017 American College of Radiology. https://acsearch.acr.org/docs/69369/Narrative/. Accessed 03/01/2018.